title: Ibandronate does not reduce the anabolic effects of PTH in ovariectomized rat tibiae: a microarchitectural and mechanical study.
abstract: Osteoporosis remains a challenging problem. Understanding the regulation on osteoclast and osteoblast by drugs has been of great interest. Both anabolic and anti-resorptive drugs yield positive results in the treatment of osteoporosis. However, whether the concurrent administration of parathyroid hormone (1-34) and ibandronate may offer an advantage over monotherapy is still unknown. This study, therefore, attempts to compare the efficacy of two therapeutical approaches and to investigate the beneficial effects in concurrent therapy in a rat model using three-point bending, pQCT and μCT analysis. A total of 60 female Sprague-Dawley rats of age 10 to 12 weeks were divided into 5 groups (SHAM, OVX+VEH, OVX+PTH, OVX+IBAN, OVX+PTH+IBAN) and subjected to ovariectomy or sham surgery accordingly. Low-dose parathyroid hormone (PTH) and/or ibandronate or its vehicle were administered subcutaneously to the respective groups starting from 4th week post-surgery at weekly intervals. Three rats from each group were euthanized every 2 weeks and their tibiae were harvested. The tibiae were subjected to metaphyseal three-point bending, pQCT and μCT analysis. Serum biomarkers for both bone formation (P1NP) and resorption (CTX) were studied. A total of 11 indices showed a significant difference between SHAM and OVX+VEH groups, suggesting the successful establishment of osteoporosis in the rat model. Compared to the previous studies which showed impedance from bisphosphonates in combination therapy with PTH, our study revealed that ibandronate does not block the anabolic effects of PTH in ovariectomized rat tibiae. Maximum load, strength-strain indices and serum bone formation markers of OVX+PTH+IBAN group are significantly higher than both monotherapy groups. With the proper ratio of anabolic and anti-resorptive drugs, the effect could be more pronounced.
authors.affiliation: Division of Bioengineering, National University of Singapore, Singapore.
authors.forename: Xiao
authors.initials: X
authors.lastname: Yang
authors.forename: Yong Hoow
authors.initials: YH
authors.lastname: Chan
authors.forename: Padmalosini
authors.initials: P
authors.lastname: Muthukumaran
authors.forename: Shamal
authors.initials: S
authors.lastname: Dasde
authors.forename: Swee-Hin
authors.initials: SH
authors.lastname: Teoh
authors.forename: Taeyong
authors.initials: T
authors.lastname: Lee
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000097:blood; D001696:Biomechanical Phenomena / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects; D016723:Bone Remodeling / Q000187:drug effects; D024042:Collagen Type I / Q000097:blood; D004164:Diphosphonates / Q000494:pharmacology*; D005260:Female; D006801:Humans; D000077557:Ibandronic Acid; D010012:Osteogenesis / Q000187:drug effects; D010052:Ovariectomy; D010281:Parathyroid Hormone / Q000494:pharmacology*; D010446:Peptide Fragments / Q000097:blood; D010455:Peptides / Q000097:blood; D011347:Procollagen / Q000097:blood; D051381:Rats; D017207:Rats, Sprague-Dawley; D013977:Tibia / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology*; D055114:X-Ray Microtomography
chemical_list: D015415:Biomarkers; D024042:Collagen Type I; D004164:Diphosphonates; D010281:Parathyroid Hormone; D010446:Peptide Fragments; D010455:Peptides; D011347:Procollagen; C052929:collagen type I trimeric cross-linked peptide; C047202:procollagen Type I N-terminal peptide; D000077557:Ibandronic Acid